Bacillus Calmette-Guérin Therapy: Optimizing Outcomes amid Challenges.

Area of Science:

• Oncology
• Immunology
• Urology

Background:

• Bacillus Calmette-Guérin (BCG) is the standard adjuvant immunotherapy for non-muscle invasive bladder cancer (NMIBC).
• Clinical use of BCG is limited by supply shortages, intolerance, and inconsistent efficacy.
• There is a growing need for alternative and optimized treatment strategies for NMIBC.

Purpose of the Study:

• To review the immunologic principles, effectiveness, and limitations of BCG therapy.
• To examine alternative administration methods and combination therapies for NMIBC.
• To outline emerging treatments for BCG-unresponsive bladder cancer and provide management recommendations.

Main Methods:

• Literature review of immunologic basis, clinical efficacy, and limitations of BCG.
• Evaluation of alternative BCG administration strategies.
• Assessment of combination therapies, biomarker-based patient selection, and novel agents for BCG-unresponsive disease.

Main Results:

• BCG's efficacy is well-established but variable, with significant challenges in supply and tolerability.
• Alternative administration schedules and combination approaches show promise in enhancing BCG effectiveness.
• Emerging therapies offer new options for patients with BCG-refractory or BCG-unresponsive NMIBC.

Conclusions:

• Optimizing BCG use through modified administration and patient selection is critical.
• Biomarker-driven approaches are essential for personalizing NMIBC treatment.
• Novel therapeutic strategies are expanding options for managing advanced or refractory NMIBC.